OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2001 Individual Investigator Grant Recipient – Bin Ye

Bin Ye, Ph.D.
Dana Farber Cancer Institute/Brigham and Women’s Hospital
Finding Serum and Urine Protein/Peptide Markers of Ovarian Cancer for Screening

Project Summary

The best prospect for immediately improving ovarian cancer survival will be the development of new screening and diagnostic tests. This research project aims to screen and identify candidate serum and urine protein markers for ovarian cancer diagnosis. These markers will be valuable in understanding the pathological mechanisms in ovarian cancer development at both molecular and biochemical levels.

Using a comprehensive specimen bank of serum and urine samples collected pre-operatively in patients coming to surgery for a pelvic mass, Dr. Ye and his team will use a new technique, Surface-Enhanced Laser Desorption/Ioniazation (SELDI) mass spectrometry, to identify protein profiles that distinguish who did and did not have ovarian cancer at the time of operation. Dr. Ye will then apply liquid chromatography to further characterize and identify the potential biomarker. An interesting candidate protein or peptide will then be sequenced.

The next phase will involve the development of a practical assay method for the most useful biomarkers. If the protein is known, Dr. Ye plans to use the antibody to confirm its different expression in sera or urine. For a more accurate protein assay, a program will be developed for large population screening. If it is an unknown protein, the monoclonal or polyclonal antibody will be raised and purified for protein quantitative assay. The clinical value of a biomarker with cancer stages, sensitivity, and specificity, as well as data of CA-125, will then be investigated.